Research programme: anti-infective therapeutics - Enumeral/ICAV

Drug Profile

Research programme: anti-infective therapeutics - Enumeral/ICAV

Latest Information Update: 24 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enumeral Biomedical Holdings
  • Class Anti-infectives; Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Infections

Most Recent Events

  • 24 Apr 2017 Enumeral and ICAV agree to co-develop anti-infective therapeutics in USA for infections
  • 24 Apr 2017 Early research in Infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top